Apolipoprotein E genotypic frequencies among down syndrome patients imply early unsuccessful aging for ApoE4 carriers

Rejuvenation Research

Volumn 10, Issue 3, 2007, Pages 293-299

  Forte, Giusi I ^a   Piccione, Maria ^a   Scola, Letizia ^a   Crivello, Antonino ^a   Galfano, Cristina ^a   Corsi, Massimiliano M ^b   Chiappelli, Martina ^c   Candore, Giuseppina ^a   Giuffrè, Mario ^a   Verna, Roberto ^d   Licastro, Federico ^c   Corsello, Giovanni ^a   Caruso, Calogero ^a   Lio, Domenico ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; COPPER ZINC SUPEROXIDE DISMUTASE; GENE PRODUCT; STRESS INDUCIBLE FACTOR; TRANSCRIPTION FACTOR ETS 2; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGING; ALZHEIMER DISEASE; ARTICLE; CHILD; CHROMOSOME 21; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGING; APOLIPOPROTEIN E4; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; PROGNOSIS; SEQUENCE ANALYSIS, DNA;

EID: 34548492742     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2006.0525     Document Type: Article

References (41)

1. Cuadrado E, Barrena MJ. Immune dyfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 1996;78:209-214.
2. Mastroiacovo P, Bertollini R, Corchia C. Survival of children with Down syndrome in Italy. Am J Med Genet 1992;42:208-212.
3. Lott IT, Head E. Alzheimer disease and Down's syndrome: factors in pathogenesis. Neurobiol Aging 2005;26:383-389.
4. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
5. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
6. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
7. Lio D, Scola L, Colonna-Romano G, Candore G, Caruso C. Immunological and immunogenetic markers in sporadic Alzheimer's Disease. Aging Clin Exp Res 2006;18:163-166.
8. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29-32.
9. Corder EH, Lannfelt L, Viitanen M, Corder LS, Manton KG, Winblad B, Basun H. Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. Arch Neurol 1996;53:418-422
10. Corder EH, Basun H, Fratiglioni L, Guo Z, Lannfelt L, Viitanen M, Corder LS, Manton KG, Winblad B. Inherited frailty - APOE alleles determine survival after a diagnosis of heart disease or stroke at ages 85+. Ann NY Acad Sci 2000;908:295-298.
11. Corder EH, Lannfelt L, Viitanen M, Corder LS, Winblad B. Does apolipoprotein E polymorphism determine the survivability of vascular accidents at advanced ages? Implications for mortality differentials. In: Yi Z, Crimmins E, Carriere Y, Robine J-M, (eds.): Longer Life and Healthy Aging. Norwell, MA: Kluwer Academic Publisers, 2005, pp. 141-150.
12. Schupf N, Sergievsky GH. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 2002;180:405-410.
13. Anello G, Gueant J, Romano C, Barone C, Pettinato R, Pillot T, Rodriguez R, Romano A, Bosco P. Allele var.epsilon4 of apolipoprotein E gene is less frequent in Down's syndrome patient of the Sicilian population and has no influence on the grade of mental retardation. Neurosci Lett 2001;306:129-131.
14. Avramopoulos D, Mikkelsen M, Vassilopoulos D, Grigoriadou M, Petersen MB. Apolipoprotein E allele distribution in parents of Down's syndrome children. Lancet 1996;347:862-865.
15. Nagy B, Ban Z, Toth-Pal E, Papp C, Fintor L, Papp Z. Apolipoprotein E allele distribution in trisomy 13, 18 and 21 conceptuses in a Hungarian population, Am J Clin Pathol 2000;113:535-538.
16. Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, Cavallone L, Franceschi C, Caruso C. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun 2002;3:30-33.
17. Scola L, Candore G, Colonna-Romano G, Crivello A, Forte GI, Paolisso G, Franceschi C, Lio D, Caruso C. Study of the association with -330T/G IL-2 in a population of centenarians from centre and south Italy. Biogerontology 2005;6:425-429.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998;16:1215.
19. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
20. Rosano A, Marchetti S. Sopravvivenza delle persone con sindrome di Down in Italia. Difesa Sociale 2003;82:13-22.
21. Lund-Katz S, Wehrli S, Zaiou M, Newhouse Y, Weisgraber KH, Phillips MC. Effects of polymorphism on the microenvironment of the LDL receptor-binding region of human apoE. J Lipid Res 2001;42:894-901.
22. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003;9:94-101.
23. Barbagallo CM, Polizzi F, Severino M, Rizzo M, Vivona N, Onorato F, Caldarella R, Cefalu AB, Noto D, Notarbartolo A, Averna MR. ApoE polymorphism in a small Mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size. Eur J Epidemiol 2001;17:707-713.
24. Robitaille N, Cormier G, Couture R, Bouthillier D, Davignon J, Perusse L. Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. Hum Biol 1996;68: 357-370.
25. Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res 1986;27:227-235.
26. Hallmann DM. The apolipoprotein E polymorphism, a comparison of allele frequencies and effects in nine population. Am J Hum Genet 1991;49:338-349.
27. Gomez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999;147: 167-176.
28. Corbo RM, Scacchi R, Mureddu L, Mulas G, Alfano G. Apolipoprotein E polymorphism in Italy investigated in native plasma by a simple polyacrylamide gel isoelectric focusing technique. Comparison with frequency data of other European populations. Ann Hum Genet 1995;59:197-209.
29. Pallaud C, Stranieri C, Sass C, Siest G, Pignatti F, Visvikis S. Candidate gene polymorphisms in cardiovascular disease: a comparative study of frequencies between a French and an Italian population. Clin Chem Lab Med 2001;39:146-154.
30. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, Kafatos A, Martins MC, Sans S, Sass C, Visvikis S, De Backer G, Siest G. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 2000;152:475-488.
31. Bosco P, Gueant-Rodriguez RM, Anello G, Spada RS, Romano A, Caraci F, Ferri R, Gueant JL. Allele epsilon 4 of APOE is a stronger predictor of Alzheimer risk in Sicily than in continental South Italy. Neurosci Lett 2005;388:168-172.
32. Ewbank DC. The APOE gene and differences in life expectancy in Europe. J Gerontol A Biol Sci Med Sci 2004;59:16-20.
33. Finch CE. Developmental origins of aging in brain and blood vessels: an overview. Neurobiol Aging 2005;26:281-291.
34. Nikolaienko O, Nguyen C, Crinc LS, Cios KJ, Gardiner K. Human chromosome 21/Down syndrome gene function and pathway database. Gene 2005;364: 90-98.
35. Caruso C, Candore G, Colonna-Romano G, Lio D, Franceschi C. Inflammation and life-span. Science 2005;307:208-209.
36. Zigman WB, Jenkins EC, Tycko B, Schupf N, Silverman W. Mortality is associated with apolipoprotein E epsilon4 in nondemented adults with Down's syndrome. Neurosci Lett 2005;390:93-97.
37. Martins R, Clarnete R, Fisher C, Broe G, Brooks W, Montgomery P, Gandy SE. APOE genotype in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. NeuroReport 1995;6: 1513-1516.
38. Lucarelli P, Piciullo A, Verdecchia M, Palmarino M, Arpino C, Curatolo P. The role of -850 tumor necrosis factor-alpha and apolipoprotein E genetic polymorphism in patients with Down's syndrome-related dementia. Neurosci Lett 2003;352:29-32.
39. Deb S, Braganza J, Norton N, Williams H, Kehoe PG, Williams J, Owen MJ. APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. Br J Psychiatry 2000;176:468-472.
40. Mann DA, Pickering-Brown SM, Siddons MA, Iwatsubo T, Ihara Y, Asami-Odaka A, Suzuki N. The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype. Neurosci Lett 1995;196: 105-108.
41. Coppus T, Evenhuis HM, Verberne GJ, Visser FE, Eikelenboom P, van Gool WA, van Duijn CM. The impact of Apolipoprotein E on dementia and mortality in people with Down's syndrome. J Appl Res Intellect Disab 2006;19:251.